These results suggest that plasma, serum, or urine samples may complement PSA screening for prostate cancer diagnosis, although the positive link between GSTP1 methylation and pathological stage needs to be evaluated in more studies. The gene discussed is GSTP1; the disease is prostate carcinoma.